Recursion Pharmaceuticals Inc
RXRX5.490USD
-0.030-0.54%
Close 10/03, 16:00（ET）Quotes delayed by 15 min
2.37BMarket Cap
LossP/E TTM
More Details of Recursion Pharmaceuticals Inc Company
Recursion Pharmaceuticals, Inc. is a clinical-stage TechBio company decoding biology to industrialize drug discovery. Its Recursion Operating System (OS), a platform built across diverse technologies, enables the Company to map and navigate trillions of biological and chemical relationships within the Recursion Data Universe. The Company integrates physical and digital components as iterative loops of atoms and bits scaling wet lab biology and chemistry data organized into virtuous cycles with computational tools to rapidly translate in silico hypotheses into validated insights and novel chemistry. Its clinical programs include REC-994, REC-2282, REC-4881 and REC-3964. REC-994 is an orally bioavailable, superoxide scavenger small molecule being development for the treatment of symptomatic cerebral cavernous malformation (CCM). REC-2282 for the potential treatment of neurofibromatosis type 2. REC-3964 for the prevention of recurrent Clostridioides difficile infection.
Recursion Pharmaceuticals Inc Info
Ticker SymbolRXRX
Company nameRecursion Pharmaceuticals Inc
IPO dateApr 16, 2021
CEODr. Christopher Gibson, Ph.D.
Number of employees840
Security typeOrdinary Share
Fiscal year-endApr 16
Address41S Rio Grande Street
CitySALT LAKE CITY
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code84101
Phone13852690203
Websitehttps://www.recursion.com/
Ticker SymbolRXRX
IPO dateApr 16, 2021
CEODr. Christopher Gibson, Ph.D.
Company Executives of Recursion Pharmaceuticals Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Dean Y. Li, M.D., Ph.D.
Dr. Dean Y. Li, M.D., Ph.D.
Independent Director
Independent Director
3.20M
+0.06%
Mr. Ben R. Taylor
Mr. Ben R. Taylor
Chief Financial Officer, President of Recursion UK
Chief Financial Officer, President of Recursion UK
147.47K
-4.57%
Mr. Zavain Dar
Mr. Zavain Dar
Independent Director
Independent Director
138.76K
+2.17%
Dr. Robert M. (Rob) Hershberg, M.D., Ph.D.
Dr. Robert M. (Rob) Hershberg, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
91.71K
+31.59%
Ms. Elaine D. Sun
Ms. Elaine D. Sun
Independent Director
Independent Director
47.56K
+30.12%
Dr. Christopher Gibson, Ph.D.
Dr. Christopher Gibson, Ph.D.
President, Chief Executive Officer, Co-Founder, Director
President, Chief Executive Officer, Co-Founder, Director
15.52K
--
Dr. Najat Khan, Ph.D.
Dr. Najat Khan, Ph.D.
Director, Chief Research and Development Officer, Chief Commercial Officer
Director, Chief Research and Development Officer, Chief Commercial Officer
14.63K
-20.60%
Mr. Zachary Bogue, J.D.
Mr. Zachary Bogue, J.D.
Independent Director
Independent Director
9.38K
--
Dr. Franziska Michor, Ph.D.
Dr. Franziska Michor, Ph.D.
Independent Director
Independent Director
--
--
Dr. Blake Borgeson, Ph.D.
Dr. Blake Borgeson, Ph.D.
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Dean Y. Li, M.D., Ph.D.
Dr. Dean Y. Li, M.D., Ph.D.
Independent Director
Independent Director
3.20M
+0.06%
Mr. Ben R. Taylor
Mr. Ben R. Taylor
Chief Financial Officer, President of Recursion UK
Chief Financial Officer, President of Recursion UK
147.47K
-4.57%
Mr. Zavain Dar
Mr. Zavain Dar
Independent Director
Independent Director
138.76K
+2.17%
Dr. Robert M. (Rob) Hershberg, M.D., Ph.D.
Dr. Robert M. (Rob) Hershberg, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
91.71K
+31.59%
Ms. Elaine D. Sun
Ms. Elaine D. Sun
Independent Director
Independent Director
47.56K
+30.12%
Dr. Christopher Gibson, Ph.D.
Dr. Christopher Gibson, Ph.D.
President, Chief Executive Officer, Co-Founder, Director
President, Chief Executive Officer, Co-Founder, Director
15.52K
--
Revenue Breakdown
Currency: USDUpdated: Thu, Oct 2
Currency: USDUpdated: Thu, Oct 2
FY2025Q2
FY2025Q1
No Data
By RegionUSD
Name
Revenue
Proportion
United States
11.79M
61.73%
United Kingdom
7.31M
38.27%
By Business
By Region
No Data
Shareholding Stats
Updated: Fri, Aug 15
Updated: Fri, Aug 15
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
8.43%
ARK Investment Management LLC
7.72%
Baillie Gifford & Co.
5.66%
BlackRock Institutional Trust Company, N.A.
5.60%
SB Global Advisers Ltd
3.43%
Other
69.16%
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
8.43%
ARK Investment Management LLC
7.72%
Baillie Gifford & Co.
5.66%
BlackRock Institutional Trust Company, N.A.
5.60%
SB Global Advisers Ltd
3.43%
Other
69.16%
Shareholder Types
Shareholders
Proportion
Investment Advisor
43.28%
Investment Advisor/Hedge Fund
10.46%
Venture Capital
7.26%
Sovereign Wealth Fund
3.78%
Individual Investor
2.93%
Research Firm
1.97%
Corporation
1.80%
Hedge Fund
1.52%
Bank and Trust
0.83%
Other
26.18%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
654
296.43M
69.37%
-20.49M
2025Q2
658
317.16M
74.44%
-11.74M
2025Q1
665
322.62M
81.56%
-7.38M
2024Q4
611
317.29M
80.77%
+25.35M
2024Q3
560
281.65M
104.01%
-6.72M
2024Q2
527
272.94M
105.41%
+14.66M
2024Q1
478
234.97M
104.72%
-10.28M
2023Q4
433
227.80M
110.74%
+18.50M
2023Q3
402
195.18M
97.47%
+1.19M
2023Q2
358
172.49M
89.73%
-20.74M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
The Vanguard Group, Inc.
36.00M
8.43%
+3.77M
+11.70%
Jun 30, 2025
ARK Investment Management LLC
32.99M
7.72%
-1.83M
-5.25%
Jun 30, 2025
Baillie Gifford & Co.
24.17M
5.66%
-219.20K
-0.90%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
23.93M
5.6%
+3.86M
+19.23%
Jun 30, 2025
SB Global Advisers Ltd
14.67M
3.43%
--
--
Jun 30, 2025
Kinnevik AB
13.43M
3.14%
--
--
Jun 30, 2025
Mubadala Investment Company PJSC
12.99M
3.04%
--
--
Jun 30, 2025
State Street Global Advisors (US)
11.18M
2.62%
-1.91M
-14.56%
Jun 30, 2025
Novo Holdings A/S
9.67M
2.26%
--
--
Jun 30, 2025
MIC Capital Management UK LLP
9.64M
2.26%
--
--
Jun 30, 2025
View more
Related ETFs
Updated: Thu, Oct 2
Updated: Thu, Oct 2
Name
Proportion
ARK Genomic Revolution ETF
5.18%
First Trust Nasdaq AI and Robotics ETF
1.71%
AXS Green Alpha ETF
1.19%
ARK Innovation ETF
1.18%
Franklin Genomic Advancements ETF
0.91%
Virtus LifeSci Biotech Clinical Trials ETF
0.71%
WisdomTree BioRevolution Fund
0.7%
SPDR S&P Biotech ETF
0.41%
WisdomTree Artificial Intelligence and Innov Fund
0.32%
Direxion Daily S&P Biotech Bull 3X Shares
0.25%
View more
ARK Genomic Revolution ETF
Proportion5.18%
First Trust Nasdaq AI and Robotics ETF
Proportion1.71%
AXS Green Alpha ETF
Proportion1.19%
ARK Innovation ETF
Proportion1.18%
Franklin Genomic Advancements ETF
Proportion0.91%
Virtus LifeSci Biotech Clinical Trials ETF
Proportion0.71%
WisdomTree BioRevolution Fund
Proportion0.7%
SPDR S&P Biotech ETF
Proportion0.41%
WisdomTree Artificial Intelligence and Innov Fund
Proportion0.32%
Direxion Daily S&P Biotech Bull 3X Shares
Proportion0.25%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
